INT94774

From wiki-pain
Revision as of 13:08, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2001
Last Reported 2011
Negated 7
Speculated 9
Reported most in Body
Documents 43
Total Number 52
Disease Relevance 44.41
Pain Relevance 13.99

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (CDKN2A) DNA binding (CDKN2A) protein complex (CDKN2A)
cytoplasm (CDKN2A) cytosol (CDKN2A) nucleolus (CDKN2A)
Anatomy Link Frequency
podocytes 2
melanocyte 1
duct 1
CDKN2A (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 65 99.82 Very High Very High Very High
melanocortin 1 receptor 3323 99.46 Very High Very High Very High
Chronic pancreatitis 13 98.42 Very High Very High Very High
imagery 51 78.84 Quite High
cINOD 248 53.36 Quite High
Inflammation 59 45.12 Quite Low
addiction 22 5.00 Very Low Very Low Very Low
palliative 18 5.00 Very Low Very Low Very Low
cytokine 12 5.00 Very Low Very Low Very Low
Inflammatory mediators 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 1403 100.00 Very High Very High Very High
Acute Renal Failure 166 100.00 Very High Very High Very High
Burns 295 99.98 Very High Very High Very High
Skin Cancer 335 99.90 Very High Very High Very High
Metastasis 237 99.88 Very High Very High Very High
Pancreatic Ductal Carcinoma 8 99.84 Very High Very High Very High
Aneuploidy 76 99.82 Very High Very High Very High
Stomach Cancer 432 99.70 Very High Very High Very High
Melanoma 3263 99.56 Very High Very High Very High
Tetraploidy 54 99.52 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The finding was associated to increased levels of some CDKIs, namely p27(Kip1) and p21(Cip1), whereas ASA did not affected p16(Ink4A) level at any of the concentrations employed.
Neg (not) Regulation (affected) of p16 associated with aspirin
1) Confidence 0.60 Published 2008 Journal Int J Immunopathol Pharmacol Section Abstract Doc Link 19144277 Disease Relevance 0.13 Pain Relevance 0.50
The finding was associated to increased levels of some CDKIs, namely p27(Kip1) and p21(Cip1), whereas ASA did not affected p16(Ink4A) level at any of the concentrations employed.
Neg (not) Regulation (affected) of Ink4A associated with aspirin
2) Confidence 0.60 Published 2008 Journal Int J Immunopathol Pharmacol Section Abstract Doc Link 19144277 Disease Relevance 0.13 Pain Relevance 0.50
We also explored whether the association of MC1R variants with melanoma risk differed if the CDKN2A mutations affected p16INK4a alone or both p16INK4 and p14ARF proteins.
Spec (whether) Regulation (affected) of p16INK4a associated with melanocortin 1 receptor and melanoma
3) Confidence 0.60 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.74 Pain Relevance 0.39
For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1–11 biopsies analyzed per study participant).
Regulation (spanning) of p16 associated with aneuploidy, tetraploidy and congenital anomalies
4) Confidence 0.45 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 0.62 Pain Relevance 0
For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1–11 biopsies analyzed per study participant).
Regulation (spanning) of CDKN2A associated with aneuploidy, tetraploidy and congenital anomalies
5) Confidence 0.45 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 0.62 Pain Relevance 0
and 2, thus affecting p16INK4a protein alone or both p16INK4a and p14ARF proteins (7).
Regulation (affecting) of p14ARF
6) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 1.24 Pain Relevance 0.11
Moreover, it is not known whether the associations of MC1R variants with melanoma risk in CDKN2A carriers vary, depending on whether the CDKN2A mutation alters p16INK4A protein alone or both p16INK4A and p14ARF proteins.
Spec (whether) Regulation (alters) of p14ARF associated with melanocortin 1 receptor and melanoma
7) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 1.20 Pain Relevance 0.84
We also investigated whether the associations of the frequent MC1R variants and number of MC1R variants with melanoma risk differed according to the type of CDKN2A mutations (mutations affecting p16INK4a protein only vs mutations affecting both p16INK4a and p14ARF proteins).
Regulation (affecting) of p14ARF associated with melanocortin 1 receptor and melanoma
8) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.43 Pain Relevance 1.16
We also explored whether the association of MC1R variants with melanoma risk differed if the CDKN2A mutations affected p16INK4a alone or both p16INK4 and p14ARF proteins.
Spec (whether) Regulation (affected) of p14ARF associated with melanocortin 1 receptor and melanoma
9) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.74 Pain Relevance 0.39
The median ages at examination among affected and unaffected CDKN2A mutation carriers were 47 and 41 years, respectively, in Europe; 42 and 34 years, respectively, in North America; and 54 and 47 years, respectively, in Australia.
Neg (unaffected) Regulation (unaffected) of CDKN2A
10) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.61 Pain Relevance 0.51
A total of 23 nonsynonymous MC1R variants were detected in affected and unaffected CDKN2A mutation carriers of the 186 melanoma-prone families, and four of these variants (V60L, V92M, R151C, and R160W) showed a frequency more than 5% in these mutation carriers across all continents.
Neg (unaffected) Regulation (unaffected) of CDKN2A associated with melanocortin 1 receptor and melanoma
11) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 1.08 Pain Relevance 0.49
Despite the ascertainment of the families through at least two melanoma patients, the frequencies of these four variants in unaffected CDKN2A mutation carriers were similar to those reported in control groups from the same populations (12,18).
Neg (unaffected) Regulation (unaffected) of CDKN2A associated with melanoma
12) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 1.04 Pain Relevance 0.44
The median ages at examination among affected and unaffected CDKN2A mutation carriers were 47 and 41 years, respectively, in Europe; 42 and 34 years, respectively, in North America; and 54 and 47 years, respectively, in Australia.
Neg (unaffected) Regulation (affected) of CDKN2A
13) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.61 Pain Relevance 0.52
A total of 23 nonsynonymous MC1R variants were detected in affected and unaffected CDKN2A mutation carriers of the 186 melanoma-prone families, and four of these variants (V60L, V92M, R151C, and R160W) showed a frequency more than 5% in these mutation carriers across all continents.
Neg (unaffected) Regulation (affected) of CDKN2A associated with melanocortin 1 receptor and melanoma
14) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 1.09 Pain Relevance 0.49
We also explored whether the association of MC1R variants with melanoma risk differed if the CDKN2A mutations affected p16INK4a alone or both p16INK4 and p14ARF proteins.
Spec (whether) Regulation (affected) of CDKN2A associated with melanocortin 1 receptor and melanoma
15) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.74 Pain Relevance 0.39
In our analysis, the associations of MC1R variants with melanoma risk did not differ statistically significantly depending on whether CDKN2A mutations altered only the p16INK4a protein or both p16INK4a and p14ARF proteins.
Spec (whether) Regulation (altered) of p14ARF associated with melanocortin 1 receptor and melanoma
16) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.54 Pain Relevance 0.98
Moreover, a number of other genetic alterations for several specific genes including p53, p16INK4a, and Smad4, have been documented [58].
Regulation (alterations) of p16INK4a
17) Confidence 0.44 Published 2011 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2964042 Disease Relevance 0.80 Pain Relevance 0
We also investigated whether the associations of the frequent MC1R variants and number of MC1R variants with melanoma risk differed according to the type of CDKN2A mutations (mutations affecting p16INK4a protein only vs mutations affecting both p16INK4a and p14ARF proteins).
Regulation (affecting) of p16INK4a associated with melanocortin 1 receptor and melanoma
18) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.42 Pain Relevance 1.16
We also investigated whether the associations of the frequent MC1R variants and number of MC1R variants with melanoma risk differed according to the type of CDKN2A mutations (mutations affecting p16INK4a protein only vs mutations affecting both p16INK4a and p14ARF proteins).
Regulation (affecting) of p16INK4a associated with melanocortin 1 receptor and melanoma
19) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.41 Pain Relevance 1.21
and 2, thus affecting p16INK4a protein alone or both p16INK4a and p14ARF proteins (7).
Regulation (affecting) of p16INK4a
20) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 1.22 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox